{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:30:09Z","timestamp":1761183009135,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jiac.2021.08.013","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T01:55:09Z","timestamp":1631670909000},"page":"87-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ceftolozane\/tazobactam for refractory P. aeruginosa endocarditis: A case report and pharmacokinetic analysis"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-1451","authenticated-orcid":false,"given":"Sunish","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3989-5345","authenticated-orcid":false,"given":"Derek N.","family":"Bremmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen G.","family":"Kline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan K.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"113","key":"10.1016\/j.jiac.2021.08.013_bib1","article-title":"Ein fall von pycocyaneus-sptikamie mit komplizierender. Pyocyaneous-endocarditis in kindesalter","volume":"25","author":"Blum","year":"1899","journal-title":"Centrlabl. f. Bakt."},{"issue":"12","key":"10.1016\/j.jiac.2021.08.013_bib2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-147-12-200712180-00002","article-title":"International collaboration on endocarditis prospective cohort study (ICE-PCS) investigators. Non-HACEK gram-negative bacillus endocarditis","volume":"147","author":"Morpeth","year":"2007","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.jiac.2021.08.013_bib3","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/jpc.14388","article-title":"Successful ceftolozane-tazobactam rescue therapy in a child with endocarditis caused by multidrug-resistant Pseudomonas aeruginosa","volume":"55","author":"Mart\u00edn-Caza\u00f1a","year":"2019","journal-title":"J Paediatr Child Health"},{"issue":"2","key":"10.1016\/j.jiac.2021.08.013_bib4","article-title":"Ceftolozane-tazobactam in combination with fosfomycin for treatment of MDR\/XDR P. aeruginosa infective endocarditis","author":"Prescott","year":"2019","journal-title":"Clinical Infection in Practice"},{"key":"10.1016\/j.jiac.2021.08.013_bib5","first-page":"1402320","article-title":"Multidrug resistant Pseudomonas mycotic pseudoaneurysm following cardiac transplant bridged by ventricular assistant device","volume":"2017","author":"Aye","year":"2017","journal-title":"Case Rep Infect Dis"},{"key":"10.1016\/j.jiac.2021.08.013_bib6","article-title":"Pseudomonas endocarditis in the detroit medical center,","volume":"52","author":"Reyes","year":"1973","journal-title":"1969Y1972. Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.jiac.2021.08.013_bib7","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/MD.0b013e3181b8bedc","article-title":"Resurgence of Pseudomonas endocarditis in detroit, 2006-2008","volume":"88","author":"Reyes","year":"2009","journal-title":"Medicine (Baltim)"},{"issue":"2","key":"10.1016\/j.jiac.2021.08.013_bib8","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/jac\/dkaa456","article-title":"Activity of imipenem\/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases","volume":"76","author":"Mushtaq","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.jiac.2021.08.013_bib9","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/cid\/ciy801","article-title":"Rapid molecular diagnostics to inform empiric use of ceftazidime\/avibactam and ceftolozane\/tazobactam against Pseudomonas aeruginosa: primers IV","volume":"68","author":"Evans","year":"2019","journal-title":"Clin Infect Dis"},{"year":"2015","series-title":"Zerbaxa (ceftolozane\/tazobactam) package insert","author":"Merck","key":"10.1016\/j.jiac.2021.08.013_bib10"},{"issue":"10","key":"10.1016\/j.jiac.2021.08.013_bib11","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1128\/AAC.02310-13","article-title":"Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model","volume":"58","author":"VanScoy","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2021.08.013_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00084-21","article-title":"In vitro susceptibility of multidrug-resistant Pseudomonas aeruginosa following treatment-emergent resistance to ceftolozane-tazobactam","author":"Rubio","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jiac.2021.08.013_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"6","key":"10.1016\/j.jiac.2021.08.013_bib14","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/chromsci\/bmw047","article-title":"Development of an HPLC method for the determination of ceftolozane\/tazobactam in biological and aqueous matrixes","volume":"54","author":"Sutherland","year":"2016","journal-title":"J Chromatogr Sci"},{"key":"10.1016\/j.jiac.2021.08.013_bib15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF01086153","article-title":"Pharmacokineticsof dosing regimens which utilize multiple intravenous infusions: gentamicin in bum patients","volume":"4","author":"Sawchuk","year":"1976","journal-title":"Pharmacokinet Biopharm"},{"issue":"5","key":"10.1016\/j.jiac.2021.08.013_bib16","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1002\/phar.1744","article-title":"Ceftolozane\/tazobactam pharmacokinetics in a critically ill adult receiving continuous renal replacement therapy","volume":"36","author":"Bremmer","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2021.08.013_bib17","article-title":"Modifiable risk factors for the emergence of ceftolozane-tazobactam resistance","author":"Tamma","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jiac.2021.08.013_bib18","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/jac\/dkx001","article-title":"Determining \u03b2-lactam exposure threshold to suppress resistance development in Gram-negative bacteria","volume":"72","author":"Tam","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2021.08.013_bib19","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1128\/AAC.01590-12","article-title":"In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum \u03b2-lactamases, in the thighs of neutropenic mice","volume":"57","author":"Craig","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2021.08.013_bib20","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.1128\/AAC.03572-14","article-title":"Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic\/pharmacodynamic target","volume":"58","author":"Lepak","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jiac.2021.08.013_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jiac.2021.08.013_bib22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"issue":"12","key":"10.1016\/j.jiac.2021.08.013_bib23","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.jiac.2021.08.013_bib24","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1128\/AAC.02969-15","article-title":"Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates","volume":"60","author":"Buehrle","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jiac.2021.08.013_bib25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/00005792-198605000-00006","article-title":"Left-sided endocarditis due to Pseudomonas aeruginosa. A report of 10 cases and review of the literature","volume":"65","author":"Wieland","year":"1986","journal-title":"Medicine (Baltim)"},{"issue":"6","key":"10.1016\/j.jiac.2021.08.013_bib26","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1128\/AAC.43.6.1379","article-title":"Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents","volume":"43","author":"Carmeli","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jiac.2021.08.013_bib27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.jiac.2021.08.013_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01183-17","article-title":"Emergence of ceftolozane-tazobactam-resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation","volume":"61","author":"MacVane","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.jiac.2021.08.013_bib29","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/ofid\/ofy343","article-title":"Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa over 20 Years from the SENTRY antimicrobial surveillance program, 1997-2016","volume":"6","author":"Shortridge","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"10.1016\/j.jiac.2021.08.013_bib30","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.amjcard.2020.02.035","article-title":"Contemporary trends in native valve infective endocarditis in United States (from the national inpatient sample database)","volume":"125","author":"Khan","year":"2020","journal-title":"Am J Cardiol"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X21002312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X21002312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:02:56Z","timestamp":1761159776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X21002312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1341321X21002312"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2021.08.013","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceftolozane\/tazobactam for refractory P. aeruginosa endocarditis: A case report and pharmacokinetic analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2021.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}